HJ Research delivers in-depth insights on the global Geriatric Medicines market in its upcoming report titled, Global Geriatric Medicines Market Report 2018-2029. According to this study, the global Geriatric Medicines market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on Geriatric Medicines market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the Geriatric Medicines market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Geriatric Medicines industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Geriatric Medicines industry.
Global Geriatric Medicines market: competitive landscape analysis
This report contains the major manufacturers analysis of the global Geriatric Medicines industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global Geriatric Medicines market: types and end industries analysis
The research report includes specific segments such as end industries and product types of Geriatric Medicines. The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Geriatric Medicines market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of Geriatric Medicines in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global Geriatric Medicines market include:
Eli Lilly and Company
AstraZeneca
Boehringer Ingelheim
Abbott Laboratories
Sanofi
Bristol-Myers Squibb
Merck
Novartis
Pfizer
GSK
Market segmentation, by product types:
Analgesics
Antihypertensives
Statins
Antidiabetics
Proton Pump Inhibitor
Anticoagulant
Antipsychotics
Antidepressants
Market segmentation, by applications:
Cardiovascular diseases
Arthritis
Neurological Disorders
Cancer
Osteoporosis
Respiratory
1 Industry Overview of Geriatric Medicines
1.1 Research Scope
1.2 Market Segmentation by Types of Geriatric Medicines
1.3 Market Segmentation by End Users of Geriatric Medicines
1.4 Market Dynamics Analysis of Geriatric Medicines
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of Geriatric Medicines Industry
2.1 Eli Lilly and Company
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 AstraZeneca
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 Boehringer Ingelheim
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 Abbott Laboratories
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Sanofi
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Bristol-Myers Squibb
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Merck
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.7.4 Contact Information
2.8 Novartis
2.8.1 Company Overview
2.8.2 Main Products and Specifications
2.8.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.8.4 Contact Information
2.9 Pfizer
2.9.1 Company Overview
2.9.2 Main Products and Specifications
2.9.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.9.4 Contact Information
2.10 GSK
2.10.1 Company Overview
2.10.2 Main Products and Specifications
2.10.3 Geriatric Medicines Revenue and Gross Margin (2018-2023)
2.10.4 Contact Information
3 Global Geriatric Medicines Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of Geriatric Medicines by Regions (2018-2023)
3.2 Global Sales Revenue of Geriatric Medicines by Manufacturers (2018-2023)
3.3 Global Sales Revenue of Geriatric Medicines by Types (2018-2023)
3.4 Global Sales Revenue of Geriatric Medicines by End Users (2018-2023)
4 Northern America Geriatric Medicines Market Analysis by Countries, Types and End Users
4.1 Northern America Geriatric Medicines Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America Geriatric Medicines Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America Geriatric Medicines Sales Revenue Analysis by End Users (2018-2023)
4.4 United States Geriatric Medicines Sales Revenue Analysis (2018-2023)
4.5 Canada Geriatric Medicines Sales Revenue Analysis (2018-2023)
5 Europe Geriatric Medicines Market Analysis by Countries, Types and End Users
5.1 Europe Geriatric Medicines Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe Geriatric Medicines Sales Revenue Analysis by Types (2018-2023)
5.3 Europe Geriatric Medicines Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.5 France Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.6 UK Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.7 Italy Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.8 Russia Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.9 Spain Geriatric Medicines Sales Revenue Analysis (2018-2023)
5.10 Netherlands Geriatric Medicines Sales Revenue Analysis (2018-2023)
6 Asia Pacific Geriatric Medicines Market Analysis by Countries, Types and End Users
6.1 Asia Pacific Geriatric Medicines Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Geriatric Medicines Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Geriatric Medicines Sales Revenue Analysis by End Users (2018-2023)
6.4 China Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.5 Japan Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.6 Korea Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.7 India Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.8 Australia Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.9 Indonesia Geriatric Medicines Sales Revenue Analysis (2018-2023)
6.10 Vietnam Geriatric Medicines Sales Revenue Analysis (2018-2023)
7 Latin America Geriatric Medicines Market Analysis by Countries, Types and End Users
7.1 Latin America Geriatric Medicines Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America Geriatric Medicines Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America Geriatric Medicines Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil Geriatric Medicines Sales Revenue Analysis (2018-2023)
7.5 Mexico Geriatric Medicines Sales Revenue Analysis (2018-2023)
7.6 Argentina Geriatric Medicines Sales Revenue Analysis (2018-2023)
7.7 Colombia Geriatric Medicines Sales Revenue Analysis (2018-2023)
8 Middle East & Africa Geriatric Medicines Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa Geriatric Medicines Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Geriatric Medicines Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Geriatric Medicines Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey Geriatric Medicines Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia Geriatric Medicines Sales Revenue Analysis (2018-2023)
8.6 South Africa Geriatric Medicines Sales Revenue Analysis (2018-2023)
8.7 Egypt Geriatric Medicines Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global Geriatric Medicines Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of Geriatric Medicines by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of Geriatric Medicines by Types (2024-2029)
10.3 Global Sales Revenue Forecast of Geriatric Medicines by End Users (2024-2029)
10.4 Global Revenue Forecast of Geriatric Medicines by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of Geriatric Medicines
11.1 Upstream Analysis of Geriatric Medicines
11.2 Downstream Major Consumers Analysis of Geriatric Medicines
11.3 Major Suppliers of Geriatric Medicines with Contact Information
11.4 Supply Chain Relationship Analysis of Geriatric Medicines
12 Geriatric Medicines New Project Investment Feasibility Analysis
12.1 Geriatric Medicines New Project SWOT Analysis
12.2 Geriatric Medicines New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 Geriatric Medicines Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of Geriatric Medicines
Table End Users of Geriatric Medicines
Figure Market Drivers Analysis of Geriatric Medicines
Figure Market Challenges Analysis of Geriatric Medicines
Figure Market Opportunities Analysis of Geriatric Medicines
Table Market Drivers Analysis of Geriatric Medicines
Table Eli Lilly and Company Information List
Figure Geriatric Medicines Specifications of Eli Lilly and Company
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Eli Lilly and Company (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Eli Lilly and Company (2018-2023)
Table AstraZeneca Information List
Figure Geriatric Medicines Specifications of AstraZeneca
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of AstraZeneca (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of AstraZeneca (2018-2023)
Table Boehringer Ingelheim Information List
Figure Geriatric Medicines Specifications of Boehringer Ingelheim
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Boehringer Ingelheim (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Boehringer Ingelheim (2018-2023)
Table Abbott Laboratories Information List
Figure Geriatric Medicines Specifications of Abbott Laboratories
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Abbott Laboratories (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Abbott Laboratories (2018-2023)
Table Sanofi Information List
Figure Geriatric Medicines Specifications of Sanofi
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Sanofi (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Sanofi (2018-2023)
Table Bristol-Myers Squibb Information List
Figure Geriatric Medicines Specifications of Bristol-Myers Squibb
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Bristol-Myers Squibb (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Bristol-Myers Squibb (2018-2023)
Table Merck Information List
Figure Geriatric Medicines Specifications of Merck
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Merck (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Merck (2018-2023)
Table Novartis Information List
Figure Geriatric Medicines Specifications of Novartis
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Novartis (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Novartis (2018-2023)
Table Pfizer Information List
Figure Geriatric Medicines Specifications of Pfizer
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of Pfizer (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of Pfizer (2018-2023)
Table GSK Information List
Figure Geriatric Medicines Specifications of GSK
Table Geriatric Medicines Revenue (Million USD) and Gross Margin of GSK (2018-2023)
Figure Geriatric Medicines Revenue (Million USD) and Global Market Share of GSK (2018-2023)
Table Global Revenue (Million USD) of Geriatric Medicines by Regions (2018-2023)
Table Global Revenue (Million USD) of Geriatric Medicines by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of Geriatric Medicines by Types (2018-2023)
Table Global Revenue (Million USD) of Geriatric Medicines by End Users (2018-2023)
Table Northern America Geriatric Medicines Revenue (Million USD) by Countries (2018-2023)
Table Northern America Geriatric Medicines Revenue (Million USD) by Types (2018-2023)
Table Northern America Geriatric Medicines Revenue (Million USD) by End Users (2018-2023)
Figure United States Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe Geriatric Medicines Revenue (Million USD) by Countries (2018-2023)
Table Europe Geriatric Medicines Revenue (Million USD) by Types (2018-2023)
Table Europe Geriatric Medicines Revenue (Million USD) by End Users (2018-2023)
Figure Germany Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure France Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific Geriatric Medicines Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific Geriatric Medicines Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific Geriatric Medicines Revenue (Million USD) by End Users (2018-2023)
Figure China Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure India Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America Geriatric Medicines Revenue (Million USD) by Countries (2018-2023)
Table Latin America Geriatric Medicines Revenue (Million USD) by Types (2018-2023)
Table Latin America Geriatric Medicines Revenue (Million USD) by End Users (2018-2023)
Figure Brazil Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa Geriatric Medicines Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa Geriatric Medicines Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa Geriatric Medicines Revenue (Million USD) by End Users (2018-2023)
Figure Turkey Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt Geriatric Medicines Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of Geriatric Medicines by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of Geriatric Medicines by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of Geriatric Medicines by End Users (2024-2029)
Table Major Consumers with Contact Information of Geriatric Medicines
Table Major Suppliers of Geriatric Medicines with Contact Information
Figure Supply Chain Relationship Analysis of Geriatric Medicines
Table New Project SWOT Analysis of Geriatric Medicines
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of Geriatric Medicines
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of Geriatric Medicines Industry
Table Part of References List of Geriatric Medicines Industry
Table Units of Measurement List
Table Part of Author Details List of Geriatric Medicines Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Geriatric Medicines industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the Geriatric Medicines market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from Geriatric Medicines manufacturers, Geriatric Medicines raw material suppliers, Geriatric Medicines distributors as well as buyers. The primary sources from the supply side include Geriatric Medicines manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the Geriatric Medicines raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: Geriatric Medicines industry landscape and trends, Geriatric Medicines market dynamics and key issues, Geriatric Medicines technology landscape, market opportunities, porter’s analysis and PESTEL analysis, Geriatric Medicines competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: Geriatric Medicines market size and forecast by regions, Geriatric Medicines market size and forecast by application, Geriatric Medicines market size and forecast by types, Geriatric Medicines company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
